The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study
- Conditions
- Congestive Heart FailureVenous CongestionSurgery--ComplicationsRight Heart FailureAnesthesia
- Interventions
- Diagnostic Test: Doppler assessment of portal vein flow
- Registration Number
- NCT03656263
- Lead Sponsor
- Montreal Heart Institute
- Brief Summary
Portal flow pulsatility detected by Doppler ultrasound is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse outcomes based on previous studies performed at the Montreal Heart Institute. This multicenter prospective cohort study aims to determine if portal flow pulsatility after cardiopulmonary bypass separation is associated with a longer requirement of life support after cardiac surgery.
- Detailed Description
Hypothesis: Portal flow pulsatility detected by Doppler ultrasound during cardiac surgery is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse clinical outcomes.
Background: Peri-operative right ventricular failure is associated with a high mortality rate. In this context, organ perfusion is hampered by both the reduction of cardiac output and venous congestion from the elevation of central venous pressure. The clinician's objective is to appreciate the hemodynamic impact on end-organs in an effort to adjust the therapy accordingly since the ultimate goal is to optimize their perfusion. Based on this rationale, organ specific blood flow assessment using Doppler ultrasound could be used to personalize management. In order to non-invasively assess the presence of cardiogenic portal hypertension, Doppler ultrasound can be used to detect portal flow pulsatility, an abnormal variation in the velocity of blood flow within the main portal vein. In two single-center cohort studies, the presence of portal flow pulsatility after cardiac surgery was independently associated with post-operative complications such as major bleeding, acute kidney injury (AKI) and delirium as well as increased length of intensive care unit (ICU) stay.
Specific Objectives: This multi-center cohort study aim to determine whether the association between portal flow pulsatility and organ dysfunction seen in previous studies is present across multiple cardiac surgery centers.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 360
-
Adult patients (≥18 years old) and able to give informed consent undergoing cardiac surgery with the use of CPB for whom peri-operative TEE is planned.
-
High surgical risk defined as at least one of the following:
- Multiple surgical procedures planned
- EuroSCORE II ≥ 5%
- Known pulmonary hypertension (mPAP>25mmHg or sPAP>40mmHg).
- Patient with a critical pre-operative state defined as vasopressor requirement, mechanical circulatory support, dialysis, mechanical ventilation or cardiac arrest necessitating resuscitation.
- Patient with known condition that could interfere with portal flow assessment or interpretation (liver cirrhosis, portal vein thrombosis)
- Planned cardiac transplantation
- Planned ventricular assist device implantation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description High risk cardiac surgery patients Doppler assessment of portal vein flow Defined as either: * Multiple surgical procedures planned and/or, * EuroSCORE ≥ 5% and/or, * Known pulmonary hypertension (mPAP\>25 mmHg or sPAP \> 40 mmHg)
- Primary Outcome Measures
Name Time Method Duration of invasive life support after cardiac surgery. (Tpod) Up to 28 days Defined as the time of Persistent Organ Dysfunction (POD) or Death
- Secondary Outcome Measures
Name Time Method Deep sternal wound infection or mediastinitis Up to 28 days Diagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician.
Delirium Up to 28 days Defined as a intensive care delirium screening checklist (ICDSC) score of ≥4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU)
Total duration of ICU stay in hours Up to 28 days Number of hours passed in the ICU
Duration of hospital stay (in days) Up to 28 days Number of days hospitalized from the day of surgery to discharge
All cause death Up to 28 days Death from any cause
Surgical reintervention for any reasons Up to 28 days Re-operation after the initial surgery for any cause
Major bleeding defined by the Bleeding Academic Research Consortium (BARC) Up to 28 days Perioperative intracranial bleeding within 48h Reoperation after closure of sternotomy for the purpose of controlling bleeding Transfusion of ≥5 units of whole blood of packed red blood cells within a 48 hours period Chest tube output ≥2L within a 24 hours period
Stroke Up to 28 days A central neurologic deficit persisting longer than 72 hours
Duration of mechanical ventilation (in hours) Up to 28 days Number of hours of mechanical ventilation
Acute kidney injury according to KDIGO serum creatinine criteria Up to 28 days Stage 1: ≥50% or 27 umol/L increases in serum creatinine Stage 2: ≥100% increase in serum creatinine Stage 3 ≥200% increase in serum creatinine or an increase to a level of ≥254 umol/L or dialysis initiation.
A composite outcome of major morbidity or mortality (41): including death, prolonged ventilation, stroke, renal failure (Stage ≥2), deep sternal wound infection and reoperation for any reason. Up to 28 days Composite endpoint after cardiac proposed by the Society of Thoracic Surgeons
Trial Locations
- Locations (1)
Montreal Heart Institute
🇨🇦Montreal, Quebec, Canada